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A simple and sensitive real-time reverse transcriptase–quantitative polymerase chain reaction (RT–qPCR)
was developed to quantify threonine-to-methionine substitution at amino acid position 790 (T790M)
mutant transcripts in a wild-type (wt) epidermal growth factor receptor background. The assay is based
on three unmodiﬁed oligonucleotides, and both SYBR Green and a Taqman probe can be used. To increase
the discrimination between mutant and wt signals, ARMS (ampliﬁcation refractory mutation system) and
LNA (locked nucleic acid) primers were tested, but a beneﬁt was observed only with plasmids and not
with cellular complementary DNA. The RT–qPCR assay using transcript-speciﬁc primers can detect as
few as 1% T790M transcripts in a wt background and, therefore, will be useful in RNA interference studies
speciﬁcally targeting mutant RNA.
 2009 Elsevier Inc. All rights reserved.Some lung cancer patients are initially very responsive to small
molecule tyrosine kinase inhibitors such as geﬁtinib and erlotinib.
The sensitivity of the cancer cells is caused by sensitizing muta-
tions in the epidermal growth factor receptor (EGFR).1 However,
the efﬁcacy of the inhibitors is limited in time due to the appearance
of cells with an additional resistance conferring mutation, often a
threonine-to-methionine substitution at amino acid position 790
(T790M) located in the receptor tyrosine kinase domain [1]. Many
groups have been searching for sensitive methods to detect the small
fraction of T790M mutant copies in a wild-type (wt) context. Most
assays rely on polymerase chain reaction (PCR) [2–7] and the ability
of these assays to detect genomic mutations in wt background
ranges from 1 to 25% sensitivity. Some methods claim still higher
sensitivity, but these either require specialized equipment [8], em-
ploy conceptually complex processes that may be difﬁcult to trou-
bleshoot [9], or require restriction enzyme digestion [10] that is
not easily implemented in a reverse transcriptase (RT)–PCR work-
ﬂow. Moreover, all of these assays were designed to detect muta-
tions in genomic DNA and are based on speciﬁc primer sequencesll rights reserved.
e Grève).
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efﬁcient of variation.that are located within exon 20 surrounding the T790M mutation.
For RT–PCR, however, primers should be located on exon–exon bor-
ders or located in different exons to exclude coampliﬁcation of geno-
mic sequences. The genomic methods, therefore, are not directly
applicable to transcript detection.
Here we describe a variant of an allele-speciﬁc PCR that we
more appropriately call ‘‘transcript-speciﬁc” RT–PCR (because the
term ‘‘allele” now often refers to DNA sequence variants). In our
method, total RNA is ﬁrst converted to complementary DNA
(cDNA) using a reverse primer that is common to both mutant
and wt transcripts and is located on the border of exons 20 and
21 of EGFR. Mutant- and wt-speciﬁc sequences are subsequently
ampliﬁed using transcript-speciﬁc reverse primers located in exon
20 that contain either a mutant or wt base at their 30 end and with
a common forward primer located in exon 19.
We initially designed different exon-spanning primer sets with
the point mutation T790M located in either the forward or reverse
primer and with the reverse primers used directly in cDNA synthe-
sis. With this setup, however, the results were unsatisfactory with
respect to both PCR efﬁciency and discrimination of wt and mutant
signals (data not shown). Much better results were obtained when
the cDNA synthesis was ﬁrst performed using a common reverse
primer, primer 2706R located on the exon 20/21 border (Table 1
and Fig. 1A), followed by PCR using wt- or mutant-speciﬁc primers.
The best result in terms of PCR efﬁciency and discrimination, fur-
thermore, was obtained when the reverse primer contained the
mutation site. The wt version of this primer, unfortunately,
Table 1
Primers and probe sequences for EGFR T790M mutant transcripts by real-time RT–qPCR.
Forward
primer






Primer 2510Fa CCAACAAGGAAATCCTCGAT Exon 19, nt 2510–2529 Primer 2615Ra
T790M
AGGGCATGAGCTGCA Exon 20, nt
2615–2629Primer 2525F TCGATGAAGCCTACGTGATG Exon 19/20, nt 2525–2544
Primer 2496F AACATCTCCGAAAGCCAACAAG Exon 19, nt 2496–2517




















ARMS Primer 2510Fa CCAACAAGGAAATCCTCGAT Exon 19, nt 2510–2529 Primer 2615R
T790M ARMS 1








AGGGCATGAGCAGCA Exon 20, nt
2615–2629
LNA LNA 2510F CCAACAAGGAAATCCTCGAT Exon 19, nt 2510–2529 LNA 2615R
T790M
AGGGCATGAGCTGCA Exon 20, nt
2615–2629
Probe Probe 2569 FAM-TGCCGCCTGCTGGGCAT Exon 20, nt 2569–2585
a The allele-speciﬁc primer set gaining the best PCR efﬁciency and largest discrimination, which was performed with the ARMS and LNA techniques. Bold italicized letters
identify mutations.
Fig. 1. Primers and probe locations, ampliﬁcation curves, electrophoresis gel, andmelting curves of allele-speciﬁc primers for EGFR T790Mmutant transcripts detection by real-
time RT–qPCRwith SYBRGreen. (A) The schematic shows the EGFR gene exon (boxes) and intron (lines) structure and locations of real-time RT–qPCR primers and probe: primer
2510F (CCAACAAGGAAATCCTCGAT, nt 2510–2529); primer 2615R T790M mutation (AGGGCATGAGCTGCA, nt 2615–2629); primer 2706R (TTCATGCCCTTTGCGATC, nt 2706–
2723, sitting on the border of exon 20 and exon 21); probe 2569 (FAM-TGCCGCCTGCTGGGCAT, nt 2569–2585, NM_005228.3, 5599 bp). (B) Ampliﬁcation curves with plasmids.
The Ct value with T790Mmutation plasmid was 13.90 and with wt plasmid was 24.64 (DCt = 10.74). (C) Ampliﬁcation curves with cellular cDNA. The Ct value with cDNA from
H1975was25.96andwith cDNA fromH358was33.49 (DCt = 7.53). (D) Electrophoresis gel showeda singleband for T790Mtranscript ampliﬁcation. LaneM:DNAmarker; lane1:
cDNA fromH358; lane 2: cDNA fromH1975; lane 3:wt plasmid; lane 4: T790Mmutation plasmid. (E)Melting curves showed a single peak. Red curve: cDNA fromH1975; Green
curve: T790Mmutation plasmid. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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shown). In this article, therefore, we focus on the mutant primer
set 2510F and 2615R (T790M) (Table 1 and Fig. 1A).
We also tested this setup using ARMS (ampliﬁcation refractory
mutation system) primers that include additional mismatches and
using primers that contain a 30 LNA (locked nucleic acid) residue.
Both modiﬁcations aim at increasing the difference in melting tem-
perature of the matched and unmatched primers. For ARMS prim-
ers, extra mismatches were introduced at different nucleotides
(ﬁrst, second, and third nucleotides adjacent to the T790M muta-
tion) 30 to the primer (Table 1). It was found that the ARMS primer
with the third nucleotide mismatch gained the best PCR efﬁciency
and mismatch discrimination (data not shown).
We compared the three types of primers (transcript speciﬁc,
ARMS, and LNA) on plasmid templates containing mutant and wtEGFR cDNA. The plasmids bearing an expression cassette for
EGFR–wt (kindly provided by J. Jiang, Dana-Farber Cancer Insti-
tute) were derived from the backbone of the 5.47-kb pCIneo mam-
malian expression vector (Promega). The 3.64-kb cDNA sequence
encoding EGFR–wt was cloned into the multiple cloning site
(MCS) between Xho1 and Nhe1 of the pCIneo plasmid and driven
by the cytomegalovirus promoter (pCMV). The EGFR point muta-
tion T790M in exon 20 was introduced into the tyrosine kinase do-
main of the EGFR coding sequence in the pCIneo expression vector
through the use of a GeneTailor Site-Directed Mutagenesis System
(Invitrogen). Direct sequencing of the puriﬁed PCR products was
performed using the ABI DNA sequencer (Applied Biosystems).
Real-time PCR was performed in the LightCycler 1.5 instrument,
initially with SYBR Green detection. Plasmid (250 pg) was ampli-
ﬁed with the LightCycler FastStart DNA MasterPLUS SYBR Green
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2 ll each of forward and reverse primers 10 concentrated
(500 nmol/L), 1 ll of template, and 11 ll of PCR-grade water. The
magnesium chloride concentration was 3.0 nmol/L. After a 10-
min hot start at 95 C, PCR cycles were programmed with a dena-
turation at 95 C for 10 s, annealing at 60 C for 5 s, and extension
at 72 C for 5 s. Ampliﬁcation was followed by melting curve anal-
ysis and gel electrophoresis to detect primer dimers and other non-
speciﬁc products (see Figs. 1D and 1E for transcript-speciﬁc
primers [other ﬁgures not shown]).
Thedifferencesbetween the threshold cycle (Ct) values forwt and
mutant plasmid (DCt) were 10.74 (using transcript-speciﬁc primers
[Fig. 1B]), 12.87 (using ARMS primers), and more than 16.99 (using
LNA primers). The largeDCt value of more than 16.99 obtainedwith
LNA primers would suggest that mutant transcripts could be quan-
tiﬁable in a 216.99 = 130,166.62-fold excess of wt transcripts.
However, the results turned out to be quite different when ana-
lyzing cDNA from human non-small cell lung cancer cell lines NCI-
H358 (for wt transcripts) and NCI-H1975 (these cells contain both
mutant and wt transcripts). Cellular RNA was ﬁrst isolated on the
ABI PRISM 6100 PrepStation using the AbsoluteRNA solution con-
taining DNase1 (Applied Biosystems) to remove contaminating
DNA and PCR inhibitory substances. Cellular RNA (200 ng) was con-
verted to cDNAwith the common nondiscriminating but EGFR-spe-
ciﬁc primer (primer 2706R; for sequence, see Table 1) and using
Moloney murine leukemia virus (MMLV) RT (Eurogentec) in a total
volume of 10 ll. The reverse transcription step was performed on
an Applied Biosystems ThermoCycler at 25 C for 10 min for the ini-
tial step, 30 min at 48 C for the reverse transcription step, and 95 C
for 5 min to inactivate the reverse transcription enzyme.
Although discrimination of mutant transcripts from wt tran-
scripts was again possible using transcript-speciﬁc primers
(DCt = 7.53 [Fig. 1C]) and ARMS primers (DCt = 9.12), the PCR efﬁ-
ciency was severely reduced using ARMS primers (Ct = 28.47) and
LNA primers (Ct > 41) as compared with transcript-speciﬁc primers
(Ct = 25.96), and any discrimination power was consequently lost
with LNA primers (data not shown). The behavior of our ARMS
and LNA primers may be a consequence of the much higher com-
plexity of the total cellular cDNA preparation when compared with
the plasmids containing EGFR cDNA.
We were also interested in increasing the speciﬁcity of the RT–
quantitative PCR (qPCR) by introducing a Taqman probe located in
exon 20 (Fig. 1A; probe 2569; for sequence, see Table 1). The probe
contained carboxyﬂuorescein at the 50 end and a 30 ‘‘black hole”
quencher (BHQ-1, Eurogentec). Real-time PCR was performed
using the LightCycler Taqman master mix (Roche). Using plasmid
templates, the discrimination was slightly better with the Taqman
probe (DCt = 12.08) than with SYBR Green detection (DCt = 10.74).
Using cDNA from total cellular RNA, there was no signiﬁcant differ-
ence (SYBR Green DCt = 7.53 and Taqman DCt = 7.33). The sensitiv-
ity of the Taqman assay was slightly lower, as evidenced by an
increase of the Ct value with approximately 1.56 cycles; the Ct val-
ues on wt cellular cDNA were 27.52 and 25.96 in Taqman and SYBR
Green assays, respectively, whereas on wt plasmids they were
15.88 and 13.90 in Taqman and SYBR Green assays, respectively).
To evaluate the ability of the assay to detect mutant cDNA in a
wild-type background, we ﬁrst prepared 10-fold serially diluted
T790M plasmids in a constant amount of 250 fg of wt plasmid.
Using SYBR Green detection, the mutant signal (Ct) increased line-
arly on dilution until the last dilution still above background,
which was at 2.5 fg. This implies that an amount of 1% mutant
plasmid can be detected. This sensitivity was conﬁrmed using a
higher background of 250 pg of wt plasmid and wt cDNA from
H358 cells (data not shown). To further verify the speciﬁcity of
the assay, we diluted the cDNA of H1975 cells with cDNA of normal
peripheral blood nuclear cells to provide mixtures of 100%, 10%, 1%,0.1%, 0.01%, and 0.001% mutant cDNA in wt background. The
T790M mutant transcript could still be detected with a ratio of
1:100 (data not shown). To assess the detection limit of the assay,
cDNA of H1975 cells was also diluted with distilled water to pro-
vide mixtures of 10, 1, 0.1, 0.01, 0.001, and 0.0001 ng of cDNA
(mRNA equivalent). At least 100 pg of mutant cellular cDNA could
still be detected (data not shown). The intraassay reproducibility
proved to be high; the Ct value was 27.12 ± 0.38 (mean ± SD) with
a coefﬁcient of variation (CV) of 1% in 10 independent measure-
ments for the same cDNA sample. We also tested the interassay
reproducibility with different RNA samples; for 30 independent
measurements, the Ct value was 27.05 ± 0.58 with a CV of 2% (data
not shown). The quantiﬁcation of the number of mutant transcripts
in cDNA from cells can be based on the Ct values of the pure mutant
plasmids of which the molecular weight is known and, hence, the
number of EGFR copies.
In conclusion, we have developed a simple transcript-speciﬁc
RT–PCR with a sensitivity of 1% to speciﬁcally detect and quan-
tify T790M mutant EGFR transcripts using either the SYBR Green
detection format or a Taqman probe. Transcripts harboring the
T790M resistance mutation can now be monitored in biopsies
of lung cancer patients and in culture-grown lung cancer cells
subjected to speciﬁc T790M targeted treatment by RNA
interference.
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